Orange: Minimal data to guide interaction

Label

Potential interactions

Color

Orange

Icon

Alert Outline

Displaying 201 - 280 of 280

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Raltegravir Valproic acid 325	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering, monitor for raltegravir efficacy
Raltegravir Oxcarbazepine 324	Orange: Minimal data to guide interaction	Do not coadminister: Potential for reduced levels of raltegravir	Potential decrease in antiretroviral efficacy				Consider using alternative agents
Elvitegravir Erythromycin 280	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					Use alternative agents
Elvitegravir Nefazodone 279	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nefazodone adverse effects				Use alternative agents
Elvitegravir Dexamethasone 278	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential loss of antiviral efficacy				Monitor viral load if extended dexamethasone use. Consider alternative corticosteroid for long-term use.
Elvitegravir Eluxadoline 277	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of eluxadoline adverse effects				Monitor response and titrate according to efficacy and adverse effects.
Elvitegravir Itraconazole 276	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased adverse effects from both elvitegravir and itraconazole				Monitor itraconazole concentrations. If coadministering itraconazole dose should not exceed 200 mg daily unless guided by concentrations.
Elvitegravir Tramadol 275	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased sedation				Initiate tramadol at lowest dose. If initiating elvitegravir / cobicistat, tramadol may require a dose reduction - monitor for efficacy and adverse effects to titrate.
Elvitegravir Fentanyl 274	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedation and respiratory depression				If coadministering, titrate carefully and monitor for sedation and respiratory depression
Elvitegravir Posaconazole 273	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering, monitor posaconazole concentrations.
Elvitegravir Ketoconazole 272	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased adverse effects from both elvitegravir and ketoconazole				If coadministering, ketoconazole dose should not exceed 200 mg daily.
Elvitegravir CsA 271	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased cyclosporine toxicity	Not reported			If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Tacrolimus 270	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased tacrolimus adverse effects (increased immunosuppression)				If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Sirolimus 269	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased sirolimus adverse effects (increased immunosuppression)				If coadministering, initiate lower dose of immunosuppressant, therapeutic drug monitoring is recommended, assess toxicity, consult with specialist, and adjust dose as necessary
Elvitegravir Propafenone 268	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of propafenone adverse effects				If coadministering use with caution and monitor for propafenone toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Mexiletine 267	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of mexiletine adverse effects				If coadministering use with caution and monitor for mexiletine toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Lidocaine 266	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of lidocaine adverse effects				If coadministering use with caution and monitor for lidocaine toxicity. Consider therapeutic drug monitoring and ECG if used systemically.
Elvitegravir Flecainide 265	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of flecainide adverse effects (eg, cardiac arrhythmias)				If coadministering use with caution and monitor for flecainide toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Disopyramide 264	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of disopyramide adverse effects				If coadministering use with caution and monitor for disopyramide toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Amiodarone 263	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias)				If coadministering use with caution and monitor for amiodarone toxicity. Consider therapeutic drug monitoring and ECG.
Elvitegravir Verapamil 262	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of verapamil adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Nifedipine 261	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nifedipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Nicardipine 260	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of nicardipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Felodipine 259	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of felodipine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Diltiazem 258	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of diltiazem adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Amlodipine 257	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of amlodopine adverse effects				If coadministering use with caution and monitor ECG
Elvitegravir Lofexidine 256	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of lofexidine adverse effects (e.g. orthostasis and bradycardia)				If coadministering use with caution and monitor blood pressure, heart rate, and dizziness.
Elvitegravir Fluoxetine 255	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of fluoxetine adverse effects				If coadministering start with lowest fluoxetine dose. Monitor response and titrate dose according to efficacy and adverse effects
Elvitegravir Ziprasidone 254	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of ziprasidone adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Zolpidem 253	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Flurazepam 252	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Estazolam 251	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Diazepam 250	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Clorazepate 249	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of sedative-hypnotic adverse effects				If coadministering start with low dose and titrate accordingly. Monitor for side effects.
Elvitegravir Isavuconazole 248	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering monitor isavuconazole concentrations and assess virologic response.
Elvitegravir Warfarin 247	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential over or under anticoagulation				If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Elvitegravir Dronedarone 246	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dronedarone adverse effects				If coadministering monitor for dronedarone toxicity. Consider therapeutic drug monitoring and ECG.
Elvitegravir Prednisone 245	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors				If coadministering monitor for adrenal insufficiency and Cushing's syndrome
Elvitegravir Everolimus 244	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased everolimus effects (e.g. excessive immunosuppression)				If coadministering monitor everolimus levels and adjust dose as indicated
Elvitegravir Citalopram 243	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased SSRI adverse effects				If coadministering initiate therapy with lowest citalopram dose. Monitor citalopram response and titrate dose according to efficacy and adverse effects.
Elvitegravir Escitalopram 242	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in SSRI adverse effects				If coadministering initiate escitalopram therapy with lowest dose. Monitor escitalopram response and titrate according to efficacy and adverse effects
Elvitegravir Dronabinol 241	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dronabinol adverse effects (e.g. sedation)				If coadministering initiate dronabinol at lowest dose. Monitor response and titrate according to efficacy and adverse effects.
Elvitegravir Prednisolone 240	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome, but PK / PD less affected by strong CYP3A4 inhibitors				If coadministering for systemic use, monitor for adrenal insufficiency and Cushing's syndrome. Do not coadminister if prednisolone needed for local injections.
Elvitegravir Voriconazole 239	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination					If coadministering assess risk and benefit. Consider monitoring voriconaozle concentrations.
Elvitegravir Ciclesonide 238	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				If coadministering assess risk and benefit
Elvitegravir Dutasteride 237	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of dutasteride adverse effects				If coadministering adjust dutasteride dose based on clinical effects and endogenous hormone concentrations.
Elvitegravir Dabigatran 236	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of bleeding				Dosing depends on indication and renal function. For DVT and PE, avoid co-administration if CrCL < 50 mL / min. For stroke and embolism prevention in persons with atrial fibrillation, do not coadminister in severe renal insufficiency (CrCL< 30mL / min) and consider dose reduction to 75 mg twice daily if CrCL between 30 - 50mL / min
Elvitegravir Fluvoxamine 235	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decreased elvitegravir effects				Consider using alternative antidepressant
Elvitegravir Quetiapine 234	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of quetiapine adverse effects				Consider alternative ARV therapy. For patients currently on elvitegravir / cobicistat: initiate quetiapine at lowest dose. Titrate accordingly and monitor for adverse effects. If patient already on quetiapine and requiring new elvitegravir / cobicistat: reduce queitapine to 1 / 6 of original dose before coadministering. Monitor efficacy and adverse effects.
Elvitegravir Timolol 233	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of timolol adverse effects				Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.
Elvitegravir Metoprolol 232	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of metoprolol adverse effects				Consider alternative agents. If coadministering initiate beta-blocker at low dose and titrate to clinical effect while monitoring for adverse effects.
Elvitegravir Betrixaban 231	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of bleeding				Administer single dose of betrixaban 80 mg, followed by betrixaban 40 mg once daily
Elvitegravir Testosterone 230	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased risk of testosterone adverse effects				Adjust testosterone dose based on clinical effects and endogenous hormone concentrations.
Elvitegravir Oxcarbazepine 229	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Elvitegravir Budesonide 228	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Use alternative agents
Elvitegravir Tamsulosin 227	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased tamulosin adverse effects				Use alternate agents. If coadministering, use with caution and monitor for tamulosin related adverse effects
Elvitegravir Quinidine 226	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of quinidine adverse effects (e.g. cardiac arrhythmias)				If coadministering use with caution and monitor for quinidine toxicity. Consider therapeutic drug monitoring and ECG
Elvitegravir Betamethasone 225	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of adrenal insufficiency and Cushing's syndrome				Do not coadminister if betamethasone used for local injection.
Elvitegravir Apixaban 224	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Consider avoiding combination and using alternative anticoagulant. If coadministering, reduce apixaban dose by 50% in patients who require 5-10 mg twice daily. Do not coadminister in persons who require apixaban 2.5mg twice daily.
Elvitegravir Rivaroxaban 223	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased risk of bleeding				Avoid combination and use alternative anticoagulant
Elvitegravir Ethinyl estradiol / Drospirenone 222	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased drospirenone effects (hyperkalemia); Potential decreased ethinyl estradiol effects				Additional or alternative contraception should be considered. If using, monitor potassium.
Elvitegravir LNG 221	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential increase in levonorgestrel adverse effects				Additional or alternative contraception should be considered.
Elvitegravir LDV/SOF 142	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in ledipasvir toxicity	Cmax decreased 12%, AUC increased 2%, Cmin increased 36%	90 / 400 mg once daily	Ledipasvir Cmax increased 63%, AUC increased 78%, Cmin increased 91%; Sofosbuvir Cmax increased 33%, AUC increased 36%; Sofosbuvir metabolite Cmax increased 33%, AUC increased 44%, Cmin increased 53%	Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. If coadministering, monitor for tenofovir renal toxicity. May coadminister with Genvoya.
Elvitegravir SOF/VEL 139	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir.	Cmax and AUC decreased 7%; Cmin decreased 3%	400 / 100 mg once daily	Velpatasvir Cmax increased 5%, AUC increased 19%, Cmin increased 37%; Sofosbuvir Cmax increased 1%, AUC increased 24%; Sofosbuvir metabolite Cmax increased 13%, AUC increased 35%, Cmin increased 45%	May coadminister with caution. Monitor for adverse reactions associated with TDF
Elvitegravir LDV/SOF 138	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in ledipasvir toxicity	AUC increased 11%, Cmin increased 46%	90 / 400 mg once daily	Ledipasvir Cmax increased 65%, AUC increased 79%, Cmin increased 93%; Sofosbuvir Cmax increased 28%, AUC increased 47%; Sofosbuvir metabolite Cmax increased 29%, AUC increased 48%, Cmin increased 66%%	Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. May coadminister with Genvoya.
Elvitegravir EE/NGM 137	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential for increased norgestimate effects (e.g. insulin resistance, dyslipidemia, acne, venous thrombosis); Potential decreased ethinyl estradiol effects	Not reported	0.18 / 0.215 / 0.250 mg NGM once daily, 0.025 mg EE once daily	Ethinyl estradiol Cmax decrease 6%, AUC decrease 25%, Cmin decrease 44%; Norgestimate Cmax increased 108%, AUC increased 126%, Cmin increased 167%	Additional or alternative contraception should be considered.
Elvitegravir Digoxin 126	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential for increased digoxin adverse effects	Not reported	0.5 mg single dose	Cmax increased 41%, AUC increased 8%	If coadministering, use with caution. Monitor levels and digoxin adverse effects
Bictegravir Disopyramide 85	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential increase in disopyramide effects				If coadministering, monitor for disopyramide adverse effects
Bictegravir Dexamethasone 84	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potential decrease in bictegravir levels and antiretroviral efficacy after chronic administration				If coadministering, monitor for antiretroviral efficacy. If using long-term, consider using alternative corticosteroid or antiretroviral.
Bictegravir Voriconazole 83	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Potentially increased bictegravir adverse effects	Cmax increased 9%, AUC increased 61%	300 mg BID (fasted state)	Not reported	Consider using alternative agents; if coadministering, monitor for bictegravir adverse effects
Maraviroc Oxcarbazepine 62	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Maraviroc Eslicarbazepine 61	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Fostemsavir Simvastatin 32	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased statin exposure and risk of statin associated adverse events				If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Pitavastatin 31	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased statin exposure and risk of statin associated adverse events				If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Fluvastatin 30	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased statin exposure and risk of statin associated adverse events				If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Atorvastatin 29	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased statin exposure and risk of statin associated adverse events				If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events
Fostemsavir Doxorubicin 28	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	Increased exposure of doxorubicin				If co-adminstering, monitor for adverse effects
Fostemsavir Elbasvir / grazoprevir 27	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	Potentially increased exposure of grazoprevir and risk of ALT elevations				Avoid combination; use alternative HCV regimen
Fostemsavir SOF/VEL/VOX 26	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits benefit	Increased exposure of voxilaprevir and risk of ALT elevations				Avoid combination; use alternative HCV regimen
Fostemsavir Ethinyl estradiol / Norethindrone acetate 25	Orange: Minimal data to guide interaction	Minimal data to guide interaction, weigh risks and benefits of using this combination	Increased ethinyl estradiol exposure and increased risk of thromboembolic events	Not reported	0.030 / 1.5mg once daily	EE: Cmax increased 39%, AUC increased 40%; NE: Cmax increased 8%, AUC increased 8%	If co-adminstering, ethinyl estradiol daily dose should not exceed 30 mcg. Further caution advised if patient is at increased risk for thromboembolic events.

Subscribe to Orange: Minimal data to guide interaction